The survey of oncologists outside the US examined global access to 14 myeloma chemoimmunotherapy options and autologous stem cell transplant (ASCT), and included questions on demographics and perceived barriers.
Advertisement
Advertisement
Targeted next-generation sequencing of the full UBA1 locus was used to profile diagnostic and treatment-naïve samples.
Patients in the COMMANDS study were randomly assigned to luspatercept or epoetin alfa.
Of the patients included in the study, 67.6% were not transfusion dependent before initiating luspatercept.
Adults older than 65 and newly diagnosed with DLBCL or DLBCL/high-grade BCL with MYC and BCL2 rearrangements were surveyed.
There was previously a gap in evidence when it came to how the drug works after treatment with covalent BTK inhibitors.
The retrospective study evaluated if pacritinib increased PLT counts in the phase III PERSIST-2 and phase II PAC203 studies.
The results suggest a possible treatment strategy of selinexor followed by immunotherapy.
Tasquinimod inhibited interaction of A9, a protein associated with poor prognosis.
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Elias Jabbour, MDAssociate Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center
Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
Expert Interviews
Blood Cancers Today delivers the latest news, education, and information relevant to hematologic oncology patients and practices.
Sign up to receive Blood Cancers Today eNewsletters:
Knowledge Hubs
Trending on MashupMD
FDA
FDA approves bosutinib for pediatric patients with chronic myelogenous leukemia
NatureRevClinOncol
NatureRevClinOncolYesterday, the FDA approved the BCR-ABL1 inhibitor b
#FDA
#CML
The Lancet Haematology
Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the
The Lancet Haematology
The Lancet Haematology NEW online: results from the ph2 MASTER trial sugges
#mmsm
American Society of Clinical Oncology
Houston Chronicle
A Houston doctor’s work transformed leukemia treatment. Next up: Helping patients avoid chemotherapy
MD Anderson Cancer Center
MD Anderson Cancer CenterDespite dramatic advances in leukemia pioneered
#Leukemia
#EndCancer
